Foghorn Therapeutics (FHTX) Revenue (2020 - 2026)

Foghorn Therapeutics' Revenue history runs 7 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• In Q1 2026, Revenue fell 45.11% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $28.2 million (up 20.08% YoY), while the FY2025 annual figure was $30.9 million, up 36.75% from the prior year.
• Revenue for Q1 2026 stood at $3.3 million, down from $9.2 million in the prior quarter.
• The five-year high for Revenue was $17.5 million in Q3 2023, with the low at $2.9 million in Q4 2024.
• The 5-year median for Revenue is $5.8 million (2023), against an average of $6.5 million.
• The sharpest annual moves came in 2022 and 2024: Revenue surged 16080.49% in 2022, then sank 55.33% in 2024.
• Foghorn Therapeutics' Revenue stood at $4.2 million in 2022, then surged by 37.88% to $5.8 million in 2023, then slumped by 50.49% to $2.9 million in 2024, then surged by 223.77% to $9.2 million in 2025, then tumbled by 64.67% to $3.3 million in 2026.
• Business Quant data shows FHTX's Revenue at $3.3 million in Q1 2026, $9.2 million in Q4 2025, and $8.2 million in Q3 2025.